DrugPatentWatch Database Preview
Bempedoic acid - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for bempedoic acid and what is the scope of patent protection?
Bempedoic acid
is the generic ingredient in two branded drugs marketed by Esperion Theraps Inc and is included in two NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Bempedoic acid has twenty-two patent family members in thirteen countries.
Summary for bempedoic acid
| International Patents: | 22 |
| US Patents: | 5 |
| Tradenames: | 2 |
| Applicants: | 1 |
| NDAs: | 2 |
| Bulk Api Vendors: | 41 |
| Clinical Trials: | 10 |
| Patent Applications: | 29 |
| DailyMed Link: | bempedoic acid at DailyMed |
Recent Clinical Trials for bempedoic acid
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Esperion Therapeutics | Phase 2 |
| Esperion Therapeutics | Phase 3 |
US Patents and Regulatory Information for bempedoic acid
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Esperion Theraps Inc | NEXLETOL | bempedoic acid | TABLET;ORAL | 211616-001 | Feb 21, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Esperion Theraps Inc | NEXLETOL | bempedoic acid | TABLET;ORAL | 211616-001 | Feb 21, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for bempedoic acid
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2404890 | Start Trial |
| Hungary | E036646 | Start Trial |
| Cyprus | 1119404 | Start Trial |
| Spain | 2642216 | Start Trial |
| Slovenia | 2404890 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2004067489 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for bempedoic acid
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2404890 | 301062 | Netherlands | Start Trial | PRODUCT NAME: BEMPEDONZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT, SOLVAAT OF MENGSEL DAARVAN; REGISTRATION NO/DATE: EU/1/20/1424 20200331 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
